Showing 7881-7890 of 10400 results for "".
- EWG VERIFIED Goes Mainstream with Herbal Essences Shampooshttps://practicaldermatology.com/news/ewg-verified-goes-mainstream-with-herbal-essences-shampoos/2457544/
- Case Study: Whole Body Cryotherapy Causes Cold Burn Injuryhttps://practicaldermatology.com/news/case-study-whole-body-cryotherapy-causes-cold-burn-injury/2457547/A 71-year-old man experienced a blistering cold burn after receiving a whole-body cryotherapy treatment for back pain and arthritis, according to a
- Candela, VBF Provide Laser Treatments to Families Including a Special Toddlerhttps://practicaldermatology.com/news/candela-vbf-provide-laser-treatments-to-families-including-a-special-toddler/2457498/
- Study Highlights Unique Characteristics of Melanoma Patients Who Use Tanning Bedshttps://practicaldermatology.com/news/study-highlights-unique-characteristics-of-melanoma-patients-who-use-tanning-beds/2457509/Younger individuals and females are more likely to use tanning beds, and as a result they tend to develop melanoma earlier, according to
- Alastin Skincare's Latest Product May Become Body Contouring Procedures' New BFFhttps://practicaldermatology.com/news/alastin-skincares-latest-product-may-be-body-contouring-procedures-new-bff/2457573/
- Business News: Candela Acquires Ellipsehttps://practicaldermatology.com/news/business-news-candela-acquires-ellipse/2457616/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Latest on Compounding: FDA Proposes to Strike Three Bulk Drug Substances from Listhttps://practicaldermatology.com/news/latest-on-compounding-fda-proposes-to-strike-three-bulk-drug-substances-from-list/2457632/The FDA has issued a
- TruDerm Adds Second Dermatology Centerhttps://practicaldermatology.com/news/truderm-adds-second-dermatology-center/2457681/
- XELJANZ Receives EU Marketing Authorization for Adults with Active PsAhttps://practicaldermatology.com/news/xeljanz-receives-eu-marketing-authorization-for-adults-with-active-psa/2457706/The European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease-mod
- New Patient-Centered Panel Helps BioPharmX Define its Role in the Future of Dermatologyhttps://practicaldermatology.com/news/new-patient-centered-panel-helps-biopharmx-define-its-role-in-the-future-of-dermatology/2457721/BioPharmX Corporation has formed a Special Advisory Council of thought leaders from various disciplines to help the company embrace patient centricity in its products, pricing, and market access considerations. The advisors, who bring decades of experience in fields beyond dermatology&mda